About Charles Peloquin
Prior to coming to the University of Florida, Dr. Peloquin completed a hospital pharmacy residency at Duke University Medical Center, where he also served on the clinical staff. He also completed a fellowship in Infectious Diseases and Pharmacokinetics at the Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y. For 20 years, Dr. Peloquin was the Director of the Infectious Disease Pharmacokinetics Laboratory (IDPL) at National Jewish Health, Denver, CO. He now serves as Professor of Pharmacy and Medicine at UF, where the IDPL now is located. Dr. Peloquin and his lab are part of the UF Emerging Pathogens Institute. He has served a consultant to the FDA, CDC and WHO, and has contributed to national guidelines on the treatment tuberculosis and the treatment of opportunistic infections in patients living with AIDS.
Dr. Peloquin’s laboratory serves as a national reference center for the determination of serum concentrations for the antimycobacterial, antifungal, anti-HIV drugs, and antibacterial drugs including beta-lactams and linezolid. His research efforts focus on therapeutic drug monitoring and clinical trials for patients with advanced mycobacterial diseases.